Commitments and Contingencies (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|
Jul. 19, 2022 |
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| General and administrative expense | $ 7,512,000 | $ 5,938,000 | $ 21,643,000 | $ 14,713,000 | |
| License Agreement [Member] | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Upfront license fee | $ 50,000 | ||||
| License or royalty net revenue percentage | 3.00% | ||||
| Minimum royalty | $ 250,000 | ||||
| General and administrative expense | $ 15,000 | $ 15,000 | |||
| License Agreement [Member] | Phase 3 [Member] | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Additional payment of fee | 900,000 | ||||
| License Agreement [Member] | New Drug Application [Member] | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Additional payment of fee | $ 1,000,000 | ||||
| X | ||||||||||
- Definition Additional payment of fee. No definition available.
|
| X | ||||||||||
- Definition License Or royalty net revenue percentage. No definition available.
|
| X | ||||||||||
- Definition Upfront license fee. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|